Viking Therapeutics Q2: Confidently Continuing The Recovery

Summary

  • Viking Therapeutics' stock has outperformed the S&P 500 since its April lows, marking a solid turnaround.
  • The company's dual-track approach (injectables and oral) for VK2735 positions it well against leaders Eli Lilly and Novo Nordisk, as recent results show solid progress.
  • Strong liquidity position provides a reasonable cash runway through 2027, supporting R&D initiatives and upcoming key clinical data releases.
  • VKTX's bullish narrative is still speculative, but it could also provide potential best-in-class candidates.
  • I underscore why investors who are still bullish on the obesity drug opportunity shouldn't miss the chance to buy into VKTX before it explodes higher later.
  • Looking for a helping hand in the market? Members of Ultimate Growth Investing get exclusive ideas and guidance to navigate any climate. Learn More »

Two injectors dosing pens for subcutaneous injection of antidiabetic medication or anti-obesity medication hovering over a blue background. Yellow measuring tape around the injectors.

Alones Creative

Viking Therapeutics Stock: Outperformance Is Possible

Biotech companies (XBI) are starting to make a comeback of sorts, as XBI has even managed to outperform the broader healthcare peers (XLV) since the April lows. However, that shouldn't

A Unique Price Action-based Growth Investing Service

  • We believe price action is a leading indicator. 
  • We called the TSLA top in late 2021.
  • We then picked TSLA's bottom in December 2022.
  • We updated members that the NASDAQ had long-term bearish price action signals in November 2021.
  • We told members that the S&P 500 likely bottomed in October 2022.
  • Members navigated the turning points of the market confidently in our service.
  • Members tuned out the noise in the financial media and focused on what really matters: Price Action.

Sign up now for a Risk-Free 14-Day free trial!

This article was written by

42.83K Followers

JR Research is an opportunistic investor. He was recognized by TipRanks as a Top Analyst. He was also recognized by Seeking Alpha as a "Top Analyst To Follow" for Technology, Software, and Internet, as well as for Growth and GARP.

He identifies attractive risk/reward opportunities supported by robust price action to potentially generate alpha well above the S&P 500. He has also demonstrated outperformance with his picks.

He focuses on identifying growth investing opportunities that present the most attractive risk/reward upside potential. His approach combines sharp price action analysis with fundamentals investing.

He tends to avoid overhyped and overvalued stocks while capitalizing on battered stocks with significant upside recovery possibilities.

He runs the investing group Ultimate Growth Investing which specializes in identifying high-potential opportunities across various sectors. He focuses on ideas that has strong growth potential and well-beaten contrarian plays, with an 18 to 24 month outlook for the thesis to play out.

The group is designed for investors seeking to capitalize on growth stocks with robust fundamentals, buying momentum, and turnaround plays at highly attractive valuations.

Learn more

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About VKTX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on VKTX

Related Stocks

SymbolLast Price% Chg
VKTX
--